RAPT Therapeutics, Inc. (RAPT) Cash from Investing Activities (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed Cash from Investing Activities for 5 consecutive years, with -$843000.0 as the latest value for Q4 2024.
- Quarterly Cash from Investing Activities fell 104.08% to -$843000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $52.7 million through Dec 2024, down 49.39% year-over-year, with the annual reading at $52.7 million for FY2024, 49.39% down from the prior year.
- Cash from Investing Activities hit -$843000.0 in Q4 2024 for RAPT Therapeutics, down from $18.4 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $32.4 million in Q2 2023 to a low of -$63.7 million in Q2 2021.
- Historically, Cash from Investing Activities has averaged -$2.9 million across 5 years, with a median of $6.7 million in 2020.
- Biggest five-year swings in Cash from Investing Activities: plummeted 1437.17% in 2021 and later skyrocketed 410.16% in 2023.
- Year by year, Cash from Investing Activities stood at $15.5 million in 2020, then plummeted by 202.56% to -$15.9 million in 2021, then tumbled by 159.69% to -$41.3 million in 2022, then soared by 150.01% to $20.6 million in 2023, then tumbled by 104.08% to -$843000.0 in 2024.
- Business Quant data shows Cash from Investing Activities for RAPT at -$843000.0 in Q4 2024, $18.4 million in Q3 2024, and $19.2 million in Q2 2024.